Rocket Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Carsten Boess

Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Carsten Boess”): 62,711,345 for, 572,799 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.0% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 20,507,050 for, 116,443 withheld, 1 abstained.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: David P. Southwell

Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David P. Southwell”): 43,172,112 for, 20,112,032 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 68% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 13,024,168 for, 7,599,281 withheld, 45 abstained.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Fady Malik, M.D., Ph.D.

Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Fady Malik, M.D., Ph.D.”): 62,755,875 for, 528,269 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 20,510,612 for, 112,882 withheld.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Gaurav Shah, M.D.

Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Gaurav Shah, M.D.”): 62,808,593 for, 475,551 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.2% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 20,615,961 for, 7,532 withheld, 1 abstained.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Mikael Dolsten, M.D., Ph.D.

Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Mikael Dolsten, M.D., Ph.D.”): 59,500,907 for, 3,783,237 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 18,691,800 for, 1,931,687 withheld, 8 abstained.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Peter Fong, Ph.D.

Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Peter Fong, M.D.”): 62,067,824 for, 1,216,320 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 20,025,554 for, 597,938 withheld, 3 abstained.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: The election of seven directors named in the proxy statement to hold office until the Company's annual meeting of stockholders in 2027, until their respective successors have been duly elected and qualified or until their earlier death, resignation or removal: Roderick Wong, M.D.

Rocket Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Roderick Wong, M.D.”): 62,699,331 for, 584,813 withheld, per its Form 8-K filed May 21, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.0% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 20,510,611 for, 112,882 withheld, 1 abstained.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: The approval of the proposed stock option exchange program; and

Rocket Pharmaceuticals, Inc.’s own tally for this item (“4. Stock Option Exchange Program”): 45,582,445 for, 17,615,213 against — passed, per its Form 8-K filed May 21, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Four – Stock Option Exchange Program The Company's stockholders approved the proposed stock option exchange program as described in the 2026 Proxy Statement.”
Support: 72% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 14,219,383 for, 6,404,111 against.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.

Description as filed by funds: A non-binding, advisory vote on the compensation of our named executive officers;

Rocket Pharmaceuticals, Inc.’s own tally for this item (“3. Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers”): 61,389,376 for, 1,671,016 against — passed, per its Form 8-K filed May 21, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Three - Non-Binding Advisory Vote on the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the 2026 Proxy Statement pursuant to Section 14…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 51 managers: 20,567,877 for, 55,392 against. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 147 managers: 45,888,435 for, 1,002,876 against, 133,237 abstained, 900 not voted. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: The ratification of the appointment of Eisner Amper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026;

Rocket Pharmaceuticals, Inc.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Accounting Firm”): 79,195,009 for, 1,002,656 against — passed, per its Form 8-K filed May 21, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Two - Ratification of Appointment of Independent Registered Accounting Firm The Company's stockholders ratified the appointment of EisnerAmper LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2026 by the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 20,623,493 for, 1 against.

Showing the 25 largest of 52 asset managers. See all 52 in the interactive database.